🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being hailed as a "significant breakthrough" in the battle against superbug strains of the bacteria, according to health experts.

An International Challenge

The sexually transmitted infection are escalating around the world, with data suggesting more than 82 million infections per year. Particularly high rates are reported in the African continent and nations within the World Health Organization's designated area, which includes Mongolia and China to New Zealand. Within England, cases have reached a record high, while rates across Europe in 2023 were triple the level compared to figures for 2014.

“The approval of new treatments for gonorrhoea is an significant and necessary advancement in the context of growing infection rates, escalating drug resistance and the extremely scarce available drugs presently on offer.”

Medical experts are particularly alarmed about the rise in antibiotic-resistant strains. The global health body has classified it as a "priority pathogen". A tracking program revealed that the effectiveness of standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Therapies Receive Approval

Zoliflodacin, also known as a brand name, was approved by the US FDA in December for combating gonorrhoea. This infection can lead to major issues, including the inability to conceive. Researchers hope that targeted use of this new drug will help slow the development of resistance.

Another new antibiotic, created by the drugmaker GlaxoSmithKline, also received approval in concurrent days. This drug, which is employed against urinary tract infections, was demonstrated in studies to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin stemmed from a innovative non-profit model for drug creation. The charitable organization GARDP worked alongside the pharmaceutical company Innoviva to develop it.

“This authorization represents a huge turning point in the therapy of superbug gonorrhoea, which until now has been evolving faster than medical innovation.”

Testing Outcomes and Global Access

According to results published in a major medical journal, the new drug cured more than 90% of cases of the STI. This places it at an comparable level with the existing first-line therapy, which involves a dual-drug approach. The study included hundreds of volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, GARDP has the rights to license and sell the drug in numerous low-income and middle-income countries.

Medical professionals treating patients have voiced hope. Access to a easy-to-administer therapy such as this is seen as a "game-changer" for public health efforts. This is deemed essential to lessen the impact of the infection for people and to stop the proliferation of untreatable gonorrhoea globally.